In short
A clinical trial is underway to assess the safety, effectiveness, and other important aspects of NXT007, a new drug designed to treat severe or moderate hemophilia A. This study aims to provide valuable insights into how NXT007 works in patients with this blood clotting disorder, including those with or without factor VIII inhibitors.
At a glance
- Drug Name
- NXT007 (RO7589655)
- Condition
- Severe or Moderate Hemophilia A
- Study Phase
- Phase I/II
- Main Objective
- Evaluate safety of multiple doses
- Secondary Objectives
- Assess pharmacokinetics, immunogenicity, efficacy
- Key Inclusion Criteria
- Males, ≥40 kg, severe or moderate hemophilia A
- Key Exclusion Criteria
- Other bleeding disorders, high risk for thrombotic microangiopathy
- Primary Endpoints
- Adverse events, changes in lab results, vital signs, ECG
- Secondary Endpoints
- Pharmacokinetics, antibody development, bleeding events
- Study Duration
- 24 weeks main treatment, optional extension period
What is NXT007?
NXT007, also known as RO7589655, is a new medication being studied for the treatment of severe or moderate hemophilia A. It is classified as a humanized monoclonal modified IgG4 antibody, which is a type of protein designed to target specific molecules in the body. This medication is being developed as a solution for injection that can be administered subcutaneously (under the skin).
Medical Condition: Hemophilia A
NXT007 is being studied to treat severe or moderate hemophilia A, a genetic bleeding disorder. Hemophilia A is caused by a deficiency in a blood clotting protein called factor VIII (FVIII). People with this condition may experience prolonged bleeding after injuries or surgeries, and in severe cases, may have spontaneous bleeding into joints and muscles.
The severity of hemophilia A is determined by the amount of factor VIII in a person's blood:
- Severe hemophilia A: Less than 1 IU/dL (international unit per deciliter) of factor VIII
- Moderate hemophilia A: Between 1 and 5 IU/dL of factor VIII
Some people with hemophilia A may develop inhibitors, which are antibodies that interfere with the treatment of the condition. NXT007 is being studied for use in patients both with and without these inhibitors.
How NXT007 Works
While the exact mechanism of action is not fully described in the provided information, as a monoclonal antibody, NXT007 is designed to target specific proteins in the blood clotting process. It aims to improve blood clotting in people with hemophilia A, potentially reducing the frequency and severity of bleeding episodes.
Clinical Trial Objectives
The ongoing clinical trial for NXT007 has several objectives:
- Main objective: To evaluate the safety of multiple doses of NXT007
- Secondary objectives:
- To study how NXT007 behaves in the body (pharmacokinetics) after multiple doses
- To evaluate the body's immune response to NXT007 (immunogenicity)
- To monitor the occurrence or recurrence of factor VIII inhibitors
- To explore how effective NXT007 is in treating hemophilia A
Eligibility Criteria
The study has specific criteria for who can participate. Here are some key inclusion criteria:
- Body weight: Participants must weigh at least 40 kg (about 88 pounds)
- Gender: Only males (based on sex at birth) can participate
- Diagnosis: Participants must have severe or moderate congenital hemophilia A, with or without inhibitors against factor VIII
- Treatment history: For participants with inhibitors, they must be using or willing to switch to a specific treatment (recombinant activated factor VII) for breakthrough bleeds
There are also several exclusion criteria, including:
- Having other inherited or acquired bleeding disorders
- Being at high risk for a condition called thrombotic microangiopathy (TMA)
- Having a history of blood clots or certain heart conditions
- Having severe allergies to similar types of treatments
Study Design
The clinical trial for NXT007 is designed in several phases:
- Screening period: This occurs from 28 to 2 days before the start of treatment
- Eligibility confirmation: Participants attend a visit to confirm they meet all criteria
- Main treatment period: This lasts for 24 weeks (168 days) and includes a planned dose-escalation scheme
- Optional extension period: Participants can choose to continue treatment beyond the initial 24 weeks
- Safety follow-up period: For participants who don't continue to the extension period or who stop the treatment early
Safety and Effectiveness Measures
The study will measure several outcomes to assess the safety and effectiveness of NXT007:
- Safety measures:
- Monitoring the occurrence and severity of side effects
- Checking for changes in laboratory test results, vital signs, and heart activity (ECG)
- Effectiveness measures:
- Measuring the concentration of NXT007 in the blood over time
- Monitoring for the development of antibodies against NXT007
- Tracking the number of bleeding events over time
- Calculating the annualized bleeding rate (ABR) for different types of bleeds
This clinical trial aims to provide important information about the safety and potential effectiveness of NXT007 in treating severe or moderate hemophilia A. If successful, it could offer a new treatment option for people living with this challenging condition.